A 76-Year-Old Man With Recurrent Castrate-Sensitive Prostate Cancer

Video

Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.

Case: A 76-Year-Old Male With Recurrent Castrate-Sensitive Prostate Cancer

History

  • A 76-year-old man diagnosed with localized prostate cancer, 4 years ago
  • At that time, he underwent EBRT


Currently

  • Patient was lost to follow-up; returns due to intermittent hip pain
  • PMH: obese, BMI 32; prostate cancer; otherwise unremarkable
  • FH: No known family history of cancer
  • PE: left hip tender to palpation, slight limp and evidence of decreased weight bearing on left lower limb

Clinical workup

  • PSA 10 ng/mL; doubling time 3 months
  • Core needle biopsy with TRUS showed adenocarcinoma of prostate
    • Gleason score (4+4)
    • Bone scan revealed 2 bone metastases: 1 in the left femur 1 in the left pelvis
  • Chest/abdominal/pelvic CT scan positive for 4 pelvic lymph node metastases
  • Diagnosis: stage IV mCSPC
  • ECOG PS 1
     

Treatment and Follow-Up

  • He was started on ADT + apalutimide 240 mg qDay
  • At 3-month follow up: PSA 2 ng/mL
  • Repeat imaging showed no new lesions

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
ARX517 Shows Promising Safety and Efficacy in mCRPC

ARX517 Shows Promising Safety and Efficacy in mCRPC

December 3rd 2023
Article

No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.

Read More

First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

September 18th 2023
Podcast

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

Listen

PSA Undetectable in First Patient With mCRPC Given Cu-67 SAR-bisPSMA

PSA Undetectable in First Patient With mCRPC Given Cu-67 SAR-bisPSMA

December 2nd 2023
Article

A patient with prostate cancer in the SECuRE trial treated with 2 cycles of 67Cu-SAR-bisPSMA at the 8GBq dose level has achieved undetectable prostate specific antigen levels.

Read More

Hitting New Targets in Metastatic Prostate Cancer

Hitting New Targets in Metastatic Prostate Cancer

March 16th 2023
Podcast

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.

Listen

Behind the FDA Approval of Enzalutamide for Prostate Cancer

Behind the FDA Approval of Enzalutamide for Prostate Cancer

November 22nd 2023
Article

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

Read More

PARP Inhibitors in mCRPC Linked to High Risk of Hematological AEs

PARP Inhibitors in mCRPC Linked to High Risk of Hematological AEs

November 20th 2023
Article

The use of poly ADP ribose polymerase inhibitors in the treatment of metastatic castration-resistant prostate cancer were associated with an increased risk of hematological adverse events.

Read More